This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, R L Articles by Neidhart, J Search for Related Content PubMed PubMed Citation Articles by Davis, R L Articles by Neidhart, J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 May; 35(5): 944-947

Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy.

College of Pharmacy, University of New Mexico, Albuquerque 87131.

ABSTRACT

We retrospectively analyzed amikacin pharmacokinetics in 28 patients (mean age, 47.4 +/- 13.6 years) who received high-dose chemotherapy during a neutropenic febrile episode. Patients received an experimental protocol of high-dose anticancer chemotherapy. Amikacin pharmacokinetic parameters were calculated from two or more concentrations in serum around a single dose by the method of Sawchuck and Zaske (J. Pharmacokinet. Biopharm. 4:183-195, 1976). Predicted parameters were calculated by using standard methods. The observed amikacin volume of distribution and clearance were significantly greater and the elimination half-life was longer than predicted (0.38 +/- 0.13 versus 0.25 liter/kg [P = 0.0001], 1.51 +/- 0.92 versus 1.17 +/- 0.38 liters/h/kg [P = 0.012], and 3.8 +/- 2.4 versus 2.9 +/- 1.1 h [P = 0.011], respectively). Multivariate analysis revealed that albumin correlated negatively and creatinine correlated positively with the volume of distribution and the elimination half-life. Creatinine and the percentage below the ideal body weight correlated negatively and hematocrit correlated positively with clearance. Administration of dosage regimens based on predicted pharmacokinetic parameters yielded subtherapeutic amikacin concentrations in serum in our patients. Because of the increased dosage requirements and the need for adequate antibiotic treatment in this population, we suggest guidelines for empiric dosing for patients with advanced cancer receiving intensive chemotherapy.

This article has been cited by other articles:

• Buelga, D. S., del Mar Fernandez de Gatta, M., Herrera, E. V., Dominguez-Gil, A., Garcia, M. J. (2005). Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies. Antimicrob. Agents Chemother. 49: 4934-4941 [Abstract] [Full Text]  
• Romano, S., de Gatta, M. M. F., Calvo, M. V., Caballero, D., Dominguez-Gil, A., Lanao, J. M. (1999). Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 44: 235-242 [Abstract] [Full Text]  
• Tod, M., Lortholary, O., Seytre, D., Semaoun, R., Uzzan, B., Guillevin, L., Casassus, P., Petitjean, O. (1998). Population Pharmacokinetic Study of Amikacin Administered Once or Twice Daily to Febrile, Severely Neutropenic Adults. Antimicrob. Agents Chemother. 42: 849-856 [Abstract] [Full Text]